Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The FDA-approved monoclonal antibody treatment, Inmazeb™, is a notable success story. However, its impact on EBOV-associated disease and mortality could be further improved. One potential strategy is to combine Inmazeb™ with other direct-acting agents that target distinct aspects of the viral replication cycle.
Given that EBOV primarily emerges in under-resourced countries, addressing the costs of these treatments is crucial. Ensuring affordability and accessibility of these interventions is essential for effective disease management and control.
In summary, while significant progress has been made in developing pharmaceutical interventions for EBOV, ongoing efforts are needed to enhance their efficacy and affordability, parti…